High mobility group box-1 (HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammation

• Published in: Brain, behavior, and immunity Vol. 72; pp. 22 - 33
• Main Authors: Kigerl, Kristina A., Lai, Wenmin, Wallace, Lindsay M., Yang, Huan, Popovich, Phillip G.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.08.2018
• Subjects: Alarmins - metabolism; Alarmins - physiology; Animals; Biomarkers - blood; Brain - metabolism; Disease Models, Animal; Female; HMGB1 Protein - metabolism; HMGB1 Protein - physiology; Inflammation - metabolism; Macrophage; Macrophages - metabolism; Mice; Mice, Inbred C57BL; Microglia; Neuroinflammation; Neurons - metabolism; Neurotoxicity Syndromes - metabolism; Seizures - etiology; Signal Transduction - physiology; Spinal Cord - metabolism; Spinal Cord Injuries - immunology; Spinal Cord Injuries - metabolism; Spinal Cord Injuries - physiopathology; Spinal cord injury; Toll-Like Receptor 4 - metabolism; Neuroinflammation; Spinal cord injury; Microglia; Macrophage
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2017.11.018

•Intraspinal HMGB1 expression increases after spinal cord injury (SCI).•CNS macrophages have increased cytoplasmic HMGB1 and decreased nuclear HMGB1.•Extracellular HMGB1 elicits a neurotoxic macrophage phenotype in vivo and in vitro.•Intraspinal HMGB1 triggers microglial activation and neuron death in the ventral horn.•Delivery of an anti-HMGB1 antibody did not result in neuroprotection after SCI. Inflammation is a ubiquitous but poorly understood consequence of spinal cord injury (SCI). The mechanisms controlling this response are unclear but culminate in the sequential activation of resident and recruited immune cells. Collectively, these cells can exert divergent effects on cell survival and tissue repair. HMGB1 is a ubiquitously expressed DNA binding protein and also a potent inflammatory stimulus. Necrotic cells release HGMB1, but HMGB1 also is actively secreted by inflammatory macrophages. A goal of this study was to quantify spatio-temporal patterns of cellular HMGB1 expression in a controlled mouse model of experimental SCI then determine the effects of HMGB1 on post-SCI neuroinflammation and recovery of function. We documented SCI-induced changes in nuclear and cytoplasmic distribution of HMGB1 in various cell types after SCI. The data reveal a time-dependent increase in HMGB1 mRNA and protein with protein reaching maximal levels 24–72 h post-injury then declining toward baseline 14–28 days post-SCI. Although most cells expressed nuclear HMGB1, reduced nuclear labeling with increased cytoplasmic expression was found in a subset of CNS macrophages suggesting that those cells begin to secrete HMGB1 at the injury site. In vitro data indicate that extracelluar HMGB1 helps promote the development of macrophages with a neurotoxic phenotype. The ability of HMGB1 to elicit neurotoxic macrophage functions was confirmed in vivo; 72 h after injecting 500 ng of recombinant HMGB1 into intact spinal cord ventral horn, inflammatory CNS macrophages co-localized with focal areas of neuronal killing. However, attempts to confer neuroprotection after SCI by blocking HMGB1 with a neutralizing antibody were unsuccessful. Collectively, these data implicate HMGB1 as a novel regulator of post-SCI inflammation and suggest that inhibition of HMGB1 could be a novel therapeutic target after SCI. Future studies will need to identify better methods to deliver optimal concentrations of HMGB1 antagonists to the injured spinal cord.